Novartis supports the Southeast Asian Breast Cancer Symposium

Sep 23, 2022

Novartis is reimagining medicine to improve and extend people's lives.  As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In 2021, the full Novartis portfolio of medicines reached over 2.5 million Filipino patients. *

In observance of World Cancer Day 2021, Novartis voluntarily reduced the prices of a broad range of cancer medicines in our Oncology portfolio, including for breast cancer. Around 2000 patients in the country are currently benefiting from the various Novartis support programs.

Novartis partnered with ICanServe Foundation to develop a series of patient education videos on breast self-examination (BSE) and Advanced Breast Cancer in English, Cebuano, and  Tagalog. In line with the country's observance of Breast Cancer Awareness Month in October 2021, Novartis partnered with the Department of Health, ICanServe Foundation, and the Philippine Hospital Association to disseminate the BSE videos.

In April 2022, Novartis launch our PIK3CA testing program in collaboration with Hi-Precision Diagnostics and the Medical City to help advanced breast cancer patients and oncologists develop a customized treatment plan and improve treatment outcomes.

Novartis Philippines launches PIK3CA Testing Program for  Breast Cancer  2.jpeg

At Novartis, we’re committed to unraveling the inner workings of cancer. We tackle breast cancer with superior science, collaboration, and passion for transforming patient care. We've taken a bold approach to our research by including patient populations often neglected in clinical trials, identifying new pathways or mutations that may play a role in disease progression, and developing therapies that not only maintain but also improve quality of life for patients. Our priority is to deliver treatments proven to improve and extend lives for those diagnosed with metastatic breast cancer. We are committed to working with the breast cancer patient community and other stakeholders to help get patients the medicine they need.

*Novartis Philippines 2021 Social Environmental and Economic (SEE)  impact valuation. data on file